Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus

Clinical Immunology

Volumn 90, Issue 2, 1999, Pages 165-172

  Lopes Virella, Maria F ^a   Virella, G ^a   Orchard, Trevor J ^b   Koskinen, Sinikka ^a   Evans, Rhobert W ^b   Becker, Dorothy J ^c   Forrest, Kimberly Y Z ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SLIPPERY ROCK UNIVERSITY   (United States)

Author keywords

Anti oxidized LDL antibodies; Coronary artery disease; Diabetes mellitus; LDL immune complexes

Indexed keywords

ANTIBODY; APOLIPOPROTEIN B; CHOLESTEROL; IMMUNOGLOBULIN A; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0032951483     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1998.4631     Document Type: Article

References (52)

1. Lloyd, C. E., Kuller, L. H., Ellis, D., Becker, D. J., Wing, R. R., and Orchard, T. J., Coronary artery disease in IDDDM, Gender differences in risk factor but not risk. Atheroscl. Thromb. Vasc. Biol. 16, 720-726, 1996.
2. Maser, R. E., Wolfson, S. K. Jr., Ellis, D., Stein, E. A., Drash, A. L., Becker, D. J., Dorman, J. S., and Orchard, T. J., Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: Interactions and risk factor profiles. Pittsburgh Epidemiology of Diabetes Complications Study (V). Arterioscl. Thromb. 11, 958-965, 1991.
3. Orchard, T. J., Dorman, J. S., Maser, R. E., Becker, D. J., Drash, A. L., Ellis, D., LaPorte, R. E., and Kuller, L. H., Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study (II). Diabetes 39, 1116-1124, 1990.
4. Koivisto, V. A., Stevens, L. K., Mattock, M., Ebeling, P., Muggeo, M., Stephenson, J., and Idzior-Walus, B., Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19, 689-697, 1996.
5. Krolewski, A. S., Kosinski, E. J., Warram, J. H., Leland, O. S., Buscik, E. J., Asmal, A. C., Rand, L. J., Christlieb, A. R., Bradley, R. F., and Kahn, C. R., Magnitude and determinants of coronary heart disease in juvenile-onset, insulin-dependent diabetes mellitus. Am. J. Cardiol. 59, 750-755, 1987.
6. Ebeling, P., and Koivisto, V. A., Occurrence and interrelationships of complications in insulin-dependent diabetes in Finland. Acta Diabetol. 34, 33-38, 1997.
7. Bellomo, G., Maggi, E., Poli, M., Agosta, F. G., Bolatti, P., and Finardi, G., Auto-antibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 44, 60-66, 1995.
8. Vlassara, H., Bucala, R., and Striker, L., Biology of disease: Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 70, 138-151, 1994.
9. Cohen, M. P., Lautenslager, G., and Shea, E., Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur. J. Clin. Chem. Clin. Biochem. 31, 707-713, 1993.
10. Fogelman, A. M., Schechter, I., Seager, J., Hokom, M., Child, J. S., and Edwards, P. A., Malondialdehyde alteration of low density lipoproteins leads to cholesterol ester accumulation in human monocytes/macrophages. Proc. Natl. Acad. Sci. USA 77, 2214-2218, 1980.
11. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., and Witztum, J. L., Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N. Eng. J. Med. 320, 915-924, 1989.
12. Hoff, H. F., O'Neil, J., Chisolm, G. M., Cole, T. B., Quehenberger, O., Esterbauer, H., and Jurgens, G., Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 9, 538-549, 1989.
13. Steinbrecher, U. P., Zhang, H. F., and Lougheed, M., Role of oxidatively modified LDL in atherosclerosis. Free Radical Biol. Med. 9, 155-168, 1990.
14. Lopes-Virella, M. F., Klein, R. L., Lyons, T. J., Stevenson, H. C., and Witztum, J. L., Glycosylation of LDL enhances CE synthesis in human monocyte-derived macrophages. Diabetes 37, 550-557, 1988.
15. Quinn, M. T., Parthasarathy, S., and Steinberg, D., Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low-density lipoprotein. Proc. Natl. Acad. Sci. USA 82, 5949-5953, 1985.
16. Quinn, M. T., Parthasarathy, S., Fong, L. G., and Steinberg, D., Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA 84, 2995-2998, 1987.
17. Berliner, J. A., Territo, M. C., Sevanian, A., Raimin, S., Kim, J. A., Bamshad, B., Esterson, M., and Fogelman, A. M., Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85, 1260-1266, 1990.
18. Kirstein, M., Brett, J., Radoff, S., Ogawa, S., Stern, D., and Vlassara, H., Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of PDGF: Role in vascular disease in diabetes and aging. Proc. Natl. Acad. Sci. USA 87, 9010-9014, 1990.
19. Steinbrecher, U. P., Eisher, M., Witztum, J. L., and Curtiss, L. K., Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: Generation of antibodies specific for derivatized lysine. J. Lipid Res. 25, 1109-1116, 1984.
20. Gonen, B., Fallon, J. J., and Baker, S. A., Immunogenicity of malondialdehyde-modified low density lipoproteins. Studies with monoclonal antibodies. Atherosclerosis 65, 265-272, 1987.
21. Tertov, V. V., Orekhov, A. N., Sayadyan, K. S., Serebrennikov, S. G., Kacharava, A. G., Lyakishev, A. A., and Smirnov, V. N., Correlation between cholesterol content and circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 81, 183-189, 1990.
22. Orekhov, A. N., Kalenich, O. S., Tertov, V. V., and Novikov, I. D., Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue Reac. 13, 233-236, 1991.
23. Lopes-Virella, M. F., Griffith, R. L., Shunk, K. A., and Virella, G. T., Enhanced uptake and impaired intracellular metabolism of LDL complexed with anti-LDL antibodies. Arterioscler. Thromb. 11, 1356-1367, 1991.
24. Griffith, R. L., Virella, G. T., Stevenson, H. C., and Lopes-Virella, M. F., LDL metabolism by macrophages activated with LDL immune complexes: A possible mechanism of foam cell formation. J. Exp. Med. 168, 1041-1059, 1988.
25. Kiener, P. A., Rankin, B. M., Davis, P. M., Yocum, S. A., Warr, G. A., and Grove, R. I., Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 15, 990-999, 1995.
26. Maggi, E., Chiesa, R., Melissano, G., Castellano, R., Astore, D., Grossi, A., Finardi, G., and Bellomo, G., LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14, 1892-1899, 1994.
27. Bergmark, C., Wu, R., De Faire, U., Lefvert, A. K., and Swedenborg, J., Patients with early-onset peripheral vascular disease have increased level of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 15, 441-445, 1995.
28. Salonen, J. T., Ylä-Herttuala, S., Yamamoto, R., Butler, S., Korpela, H., Salonen, R., Nyyssönen, K., Palinski, W., and Witztum, J. L., Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339, 883-887, 1992.
29. Puurunen, M., Manttari, M., Manninen, V., Tenkanen, L., Alfthan, G., Ehnholm, C., Vaarala, O., Aho, K., and Palosuo, T., Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 154, 2605-2609, 1994.
30. Mironova, M., Lopes-Virella, M. F., and Virella, G., Isolation and characterization of human anti-oxidized LDL autoantibodies. Arterioscler. Thromb. Vasc. Biol. 16, 222-229, 1996.
31. Virella, G., Virella, I., Leman, R. B., Pryor, M. B., and Lopes-Virella, M. F., Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23, 95-101, 1993.
32. Craig, W. Y., Autoantibodies against oxidized low density lipoprotein: a review of clinical findings and assay methodology. J. Clin. Lab. Anal. 9, 70-74, 1995.
33. Schumacher, M., Eber, B., Tatzber, F., Kaufmann, P., Esterbauer, H., and Klein, W., LDL oxidation and coronary atherosclerosis. Lancet 340, 123, 1992.
34. Boullier, A., Hamon, M., Walters-Laporte, E., Martin-Nizart, F., Mackereel, R., Fruchart, J.-C., Bertrand, M., and Duriez, P., Detection of autoantibodies against oxidized low-density lipoproteins in patients with coronary artery disease. Clin. Chim. Acta 238, 1-10, 1995.
35. Festa, A., Kopp, H. P., Shernthaner, G., and Menzel, E. J., Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41, 350-356, 1988.
36. Orchard, T. J., Virella, G., Forrest, K. Y.-Z., Becker, D. J., and Lopes-Virella, M. F. [submitted for publication]
37. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J., Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275, 1951.
38. Lopes-Virella, M. F., Sherer, G. K., Lees, A. M., Wohltmann, H., Mayfield, R., Sagel, J., Leroy, C., and Colwell, J. A., Surface binding, internalization and degradation by cultured human fibroblasts of LDL isolated from type I (insulin-dependent) diabetic patients: Changes with metabolic control. Diabetologia 22, 430-436, 1982.
39. Mironova, M., Virella, G., Virella-Lowell, I., and Lopes-Virella, M. F., Anti-modified LDL antibodies and LDL-containing immune complexes in well-controlled IDDM patients and healthy controls. Clin. Immunol. Immunopathol. 85, 73-82, 1997.
40. Triolo, G., Giadina, E., Zarcone, M. R., Giordano, C., Rinaldi, A., and Bompiani, G. D., Contribution of secretory IgA, polymeric IgA and IgA/secretory component-containing circulating immune complexes to the serum hyper-IgA in diabetes mellitus. Diabetologia 27, 157-159, 1984.
41. Koschinsky, T., Bunting, C. E., Glahn, U., Butler, S., Palinski, W., and Witztum, J. L., Increased titer of immunoglobulin A antibody to oxidized LDL in diabetic patients. Diabetes 41(Suppl. 1), 4A, 1992.
42. Palinski, W., Rosenfeld, M. E., Ylä-Herttuala, S., Gurtner, G. C., Socher, S. S., Butler, S. W., Parthasarathy, S., Carew, T. E., Steinberg, D., and Witztum, J. L., Low density lipoprotein un-dergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA 86, 1372-1376, 1989.
43. Yla-Herttuala, S., Palinski, W., Rosenfeld, M. E., Steinberg, D., and Witztum, J. L., Lipoproteins in normal and atherosclerotic aorta. Eur. Heart J. 11(Suppl. E), 88-99, 1990.
44. Itabe, H., Takeshima, E., Iwasaki, H., Kimura, J., Yoshida, Y., Imanaka, T., and Takano, T., A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. J. Biol. Chem. 269, 15274-15279, 1994.
45. Nakamura, Y., Horii, Y., Nishino, T., Shiiki, H., Sakaguchi, Y., Kagoshima, T., Dohi, K., Makita, Z., Vlassara, H., and Bucala, R., Immunochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143, 1649-1656, 1993.
46. Palinski, W., Koschinsky, T., Butler, S. W., Miller, E., Vlassara, H., Cerami, A., and Witztum, J. L., Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler. Thromb. Vasc. Biol. 15, 571-582, 1995.
47. Yla-Herttuala, S., Palinski, W., Butler, S., Picard, S., Steinberg, D., and Witztum, J. L., Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14, 32-40, 1994.
48. Virella, G., and Tsokos, G., Immune complex diseases. In "Introduction to Medical Immunology" (G. Virella, Ed.), 4th ed., pp. 475-494, Dekker, New York, 1998.
49. Tertov, V. V., Orekhov, A. N., Kacharava, A. G., Sobenin, I. A., Perova, N. V., and Smirnov, V. N., Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp. Mol. Pathol. 52, 300-308, 1990.
50. Tertov, V. V., Orekhov, A. N., Sayadyan, K. S., Serebrennikov, S. G., Kacharava, A. G., Lyakishev, A. A., and Smirnov, V. N., Correlation between cholesterol content and circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 81, 183-189, 1990.
51. Orekhov, A. N., Kalenich, O. S., Tertov, V. V., and Novikov, I. D., Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue React. 13, 233-236, 1991.
52. Emmerich, J., Bruckert, E., Delahaye, F., Thomas, D., and Richard, J. L., Relation entre HDL-cholesterol et maladies cardiovasculaires. Arch. Mal. Coeur Vaisseaux, 85 (Spec. No. 3), 21-28, 1992.